A three-step reaction sequence---enantioselectively catalyzed reduction (1 → 2), diastereoselective complexation (2 → 3), and reoxidation (3 → 4)—enables the efficient transformation of achiral 1-tetralone derivatives 1 into the corresponding chiral, nonracemic η6-tricarbonylchromium complexes. These complexes, which are thus accessible in selectable absolute configurations with 85–94% ee, are valuable building blocks for the synthesis of biologically active compounds (R1–R3 = H, OMe).
No takes yet. Share an insight, caveat, or question.
Schmalz et al. (1992) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: